MLex Comment: J&J, Synthes merger likely to attract scrutiny in trauma products sector
US healthcare group Johnson & Johnson's (J&J) 21.3 billion dollar purchase of Swiss medical device maker Synthes is expected to draw regulatory scrutiny of the companies' combined offerings in products used...To view the full article, register now.
Already a subscriber? Click here to view full article